ZYME241220P22500
- 0.00
- 0.000.00%
Zymeworks Newsroom
Express News | HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $12 Price Target
Zymeworks Hold Rating: Balancing FDA Milestones With Market Valuation and Future Risks
Leerink Partners Maintains Zymeworks(ZYME.US) With Buy Rating, Raises Target Price to $26
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
Express News | Zymeworks Inc : Leerink Partners Raises Target Price to $26 From $25
Sector Update: Health Care
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Snowflake Stimulates Lagging Market
Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
Zymeworks Announces Participation in Upcoming Investor Conferences
Express News | Zymeworks Inc - to Receive $25M Milestone Payment From Jazz Pharmaceuticals
Express News | FDA Grants U.S. Approval of Ziihera® (Zanidatamab-Hrii) for the Treatment of Adults With Previously Treated, Unresectable or Metastatic Her2-Positive (Ihc 3+) Biliary Tract Cancer (BTC)
Zymeworks Inc. (NASDAQ:ZYME) Analysts Just Slashed Next Year's Revenue Estimates By 16%
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Leerink Partners Upgrades Zymeworks(ZYME.US) to Buy Rating, Raises Target Price to $25
Zymeworks Upgraded to Outperform From Market Perform at Leerink
Express News | Zymeworks Inc : Leerink Partners Raises to Outperform From Market Perform
Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth
Zymeworks Begins Human Trials for New Cancer Therapy Targeting Ovarian and Lung Tumors
Express News | Zymeworks: Expects to Enroll Patients at Investigator Sites in North America, Europe, and Asia-Pacific Region